



Discarded Drug Program Webinar

August 2025

Welcome



Thank you for joining our **Discarded Drug Program** webinar.

- This session will be recorded and posted.
- Participants can submit questions via the Q&A feature.
- This is approximately a one-hour session with time for questions at the end.

Agenda

Topic	Presenter
Introductory Remarks	Mark Bremer, CMS
Discarded Drug Program Overview	Katie Wilder, Contractor
Refund Calculations and Timeline	Katie Wilder, Contractor
Manufacturer Payment Portal Overview	TPA Representative, Contractor
Available Resources	Katie Wilder, Contractor
Q&A Session	Suzanne Bromley, Contractor
Closing Remarks	Mark Bremer, CMS

Goals



- Provide an overview of the:
 - Discarded Drug Program
 - Calculation of refund amounts due
- Demonstrate how to:
 - Access Discarded Drug Refund Reports in the Manufacturer Payment Portal (MPP)
 - Pay any refund amounts due in MPP
- Answer your Discarded Drug Program questions

Discarded Drug Program

Manufacturers are required to provide a refund to be deposited into the Supplementary Medical Insurance (SMI) Trust Fund for the discarded amounts from drugs that meet certain criteria as stated in 42 CFR § 414.940.

Manufacturers who fail to comply with the requirement under 42 CFR § 414.940(b) will be subject to a Civil Monetary Penalty (CMP) equal to the sum of 125 percent of the assessed refund obligation.

Discarded Drug Payment Lifecycle

Manufacturers create and package single-use, single-dose drugs.

Medicare Administrative Contractors (MAC) receive claims from providers. MACs refer to the ASP pricing files or develop a payment limit for covered drugs not listed in the ASP drug pricing files.



Providers purchase drugs from distributors or directly from manufacturers.

Providers bill Medicare for drugs, using JW/JZ modifiers to report any/no discarded amounts.

MACs issue payments to the providers.

Manufacturers view their reports and pay refunds due through MPP.

Manufacturers report quarterly sales data to CMS to produce the ASP pricing files.

Providers administer drugs to Medicare patient(s).

CMS calculates the manufacturers' refund due using claims data and the ASP payment limits.

CMS loads Discarded Drug Reports into MPP.

Definition of Refundable Drug



Inclusion Criteria

- Single-source drug or biological product, including biosimilars
- Must be furnished from a singleuse package or single-dose container
- All national drug codes (NDCs)
 assigned to the drug's billing and
 payment code must be single-dose,
 as described in each product's
 labeling
- Payment is made under Medicare Part B



Exclusion Criteria

- Radiopharmaceuticals (therapeutic or diagnostic) or imaging agents
- Certain drugs or biologicals requiring filtration during preparation (prior to dilution and administration) for which unused portions must be discarded after the filtration process
- Drugs approved or licensed by the Food and Drug Administration (FDA) on or after November 15, 2021, until the last day of the sixth full quarter for which the drug has been marketed (as reported to CMS) for the first reported sale for any NDCs of such drug
- A drug approved or licensed by FDA on or after November 15, 2021 and for which the
 date the drug was first marketed (as reported to CMS) does not adequately
 approximate the date of first payment under Part B due to an applicable national
 coverage determination, until the last day of the sixth full quarter for which the drug
 has been covered and paid under Medicare Part B for the first NDC assigned to the
 billing and payment code of such drug

Tracking Discarded Drug Units



History

- Effective January 2017, providers and suppliers are required to report the JW modifier on all claims that bill for drugs and biologicals separately payable under Medicare Part B with unused and/or discarded amounts.
- Starting in **July 2023**, the JZ modifier was added to track all such drugs with no discarded amounts.



Definitions

- **Discarded amount**: Any amount of drug that is not a part of the dose and is not intended to have a therapeutic effect in the patient, up to the amount identified on the FDA-approved label.
- **JW Modifier**: Used on a Medicare Part B claim to denote the portion of the drug that was discarded.
- **JZ Modifier**: Used on a Medicare Part B claim to indicate no portion of the drug was discarded.

Applicable Percentages



An applicable percentage is essentially the **discarded amount threshold** for a specific drug. The applicable percentage is used in the calculation of the refund amount due from manufacturers. It is required to be at least **10%** but can be increased through noticeand-comment rulemaking for drugs with unique circumstances.

The following are increased applicable percentages for drugs with unique circumstances:

- 35% Drug reconstituted with a hydrogel and has variable dosing based on patient-specific characteristics
- 90% Low volume dose drug contained within 0.1 mL or less
- 45% Low volume dose drug contained within 0.11 mL up to 0.4 mL
- 26% Designated orphan drugs under Section 526 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) that are furnished to fewer than 100 unique beneficiaries per calendar year

Report Timeline

September 1, 2025

The annual Refund Report is sent to manufacturers in MPP and may include the discarded drug refund amount due for the four calendar quarters in 2024 AND updated refund amounts due, if applicable, for the four calendar quarters in 2023.

December 31, 2025

Payment is due unless a dispute is filed with CMS. Payment will be due 30 days after the dispute is resolved or by December 31, whichever is later.


February 1, 2025

Deadline for manufacturers to request an increase to their Applicable Percentage effective January 1, 2026.

October 1, 2025

The manufacturer has 30 days from the issuance of the report to file a dispute.

New Refund Quarter Calculation



Manufacturer Refund Due

Total Number of Discarded Drug Units (JW units on claims data)


ASP-Based Payment Limit

Applicable
Percentage
Multiplied by
Estimated Total
Allowed Charges

Refund Calculation when Refundable Drugs have Multiple Manufacturers

Labeler Name	Billing Units Sold	Proportion of Units Sold	Refund Due Per Manufacturer		
Labeler A	3,750	50%	\$3,750.00		
Labeler B	1,125	15%	\$1,125.00		
Labeler C	2,625	35%	\$2,625.00		
Total	7,500	100%	\$7,500.00		

Updated Refund Quarter Calculation



Updated
Manufacturer
Refund Due

Updated Total

Number of

Discarded Drug

Units (JW units

on claims data)

ASP-Based Payment Limit

Applicable Percentage
Multiplied by
Estimated Total
Allowed Charges

Refund Amount from Previous Refund Report

Onboarding Process





P Number Assignment

- A P Number is a unique identifier used in the Health Plan Management System (HPMS) to identify manufacturers and create accounts.
- Many manufacturers already have a P Number for participation in other programs, but some need a P Number issued for the Discarded Drug Program.
- Once a P Number is issued, a representative from the Third-Party Administrator (TPA) Support Center, Palmetto GBA, will contact the manufacturer.

Health Plan Management System (HPMS) Account Creation

- Manufacturers must designate their Program Type (Part B or Part B and Part D) and provide contact information for a Discarded Drug Program Contact in HPMS.
- Manufacturers must ensure that the Discarded Drug Program Contact information in HPMS is accurate at all times.



Manufacturer Payment Portal (MPP) Access


- TPA will use the Discarded Drug
 Program contact information collected
 in HPMS to assign manufacturer user
 access to the MPP.
- The Discarded Drug Program contact will be able to access reports and initiate payment for refunds due.
- The link to the new portal will be located on the home page of the TPA website (<u>www.tpadministrator.com</u>).

Requesting a P Number


Email <u>DiscardedDrugs@cms.hhs.gov</u>

- Manufacturer Legal Name
- Data Universal Numbering System (DUNS) Number
- Employer Identification Number (EIN)
- Primary Contact First and Last Name
- Primary Contact Email Address
- Primary Contact Phone Number
- Subject Line of the Email Should Read "[Manufacturer Name] Request for P Number"


TPA Website




Accessing MPP




Landing Page - No Reports




My Profile (1 of 2)




My Profile (2 of 2)



Landing Page - Reports Available




View Reports




Reports

A1 ~	$]: [\times \checkmark f]$	£ √ Report Date											
A	В	С	D	Е	F	G	Н	1	J	K	L	М	N
1 Report Date	S Code	HCPCS Long Description	Labeler Code F	Number	Report Type	Reason Code	Invoice Quarter	Invoice Year U	nits Discarded	Refund Amount Due	Adjusted Refund Amount Due	Comments	Due Date
2 09/01/2025	10001	INJECTION, TIGERMAB, 10 MG	12345 F	P8019	Updated		Q1	2023	10,986.00	(\$2,333.92)	\$0.00	Applied \$2,333.92 credit to J0001 Q2 2024	12/31/2025
3 09/01/2025	J0001	INJECTION, TIGERMAB, 10 MG	12345 F	P8019	Initial		Q1	2024	12,599.50	\$306,998.27	\$306,998.27		12/31/2025
4 09/01/2025	J0001	INJECTION, TIGERMAB, 10 MG	12345 F	P8019	Updated		Q2	2023	12,113.40	(\$7,414.14)	\$0.00	Applied \$7,414.14 credit to J0001 Q2 2024	12/31/2025
5 09/01/2025	J0001	INJECTION, TIGERMAB, 10 MG	12345 F	P8019	Initial		Q2	2024	11,399.80	\$268,167.91	\$250,593.47		12/31/2025
6 09/01/2025	J0001	INJECTION, TIGERMAB, 10 MG	12345 F	P8019	Updated		Q3	2023	9,871.60	(\$4,511.36)	\$0.00	Applied \$4,511.36 credit to J0001 Q2 2024	12/31/2025
												Received \$2,333.92 credit from J0001 Q1 2023; Received \$7,414.14 credit from J000: Q2 2023; Received \$4,511.36 credit from J0001 Q3 2023; Received \$3,315.02 credit	
7 09/01/2025	J0001	INJECTION, TIGERMAB, 10 MG	12345 F		Initial		Q3	2024	13,257.40			from J0001 Q4 2023	12/31/2025
8 09/01/2025	J0001	INJECTION, TIGERMAB, 10 MG	12345 F		Updated		Q4	2023	10,436.00	11.7		Applied \$3,315.02 credit to J0001 Q2 2024	12/31/2025
9 09/01/2025	J0001	INJECTION, TIGERMAB, 10 MG	12345 F		Initial		Q4	2024	13,036.00		\$320,869.25		12/31/2025
10 09/01/2025	J0002	INJECTION, BEARULINE ACETATE, 10 MG	23456 F	P8019	Updated		Q1	2023	4,320.00		\$0.00		12/31/2025
11 09/01/2025	J0002	INJECTION, BEARULINE ACETATE, 10 MG	23456 F	P8019	Initial		Q1	2024	760.00		\$0.00		12/31/2025
12 09/01/2025	J0002	INJECTION, BEARULINE ACETATE, 10 MG	23456 F	P8019	Updated		Q2	2023	4,220.00	\$0.00	\$0.00		12/31/2025
13 09/01/2025	J0002	INJECTION, BEARULINE ACETATE, 10 MG	23456 F	P8019	Initial		Q2	2024	210.00	\$0.00	\$0.00		12/31/2025
14 09/01/2025	J0002	INJECTION, BEARULINE ACETATE, 10 MG	23456 F	P8019	Updated		Q3	2023	200.00	\$0.00	\$0.00		12/31/2025
15 09/01/2025	J0002	INJECTION, BEARULINE ACETATE, 10 MG	23456 F	28019	Initial		Q3	2024	20.00	\$0.00	\$0.00		12/31/2025
16 09/01/2025	J0002	INJECTION, BEARULINE ACETATE, 10 MG	23456 F	8019	Updated		Q4	2023	480.00	\$0.00	\$0.00		12/31/2025
17 09/01/2025	J0002	INJECTION, BEARULINE ACETATE, 10 MG	23456 F	P8019	Initial		Q4	2024	80.00	\$0.00	\$0.00		12/31/2025
18 09/01/2025	J0003	INJECTION, LIONZOLOMIDE, 1 MG	34567 F	P8019	Updated		Q1	2023	767.00	\$0.00	\$0.00		12/31/2025
19 09/01/2025	J0003	INJECTION, LIONZOLOMIDE, 1 MG	34567 F	P8019	Initial		Q1	2024	648.00	\$0.00	\$0.00		12/31/2025
20 09/01/2025	J0003	INJECTION, LIONZOLOMIDE, 1 MG	34567 F	P8019	Updated		Q2	2023	489.00	\$0.00	\$0.00		12/31/2025
21 09/01/2025	J0003	INJECTION, LIONZOLOMIDE, 1 MG	34567 F	P8019	Initial		Q2	2024	1,025.00	\$883.91	\$883.91		12/31/2025
22 09/01/2025	J0003	INJECTION, LIONZOLOMIDE, 1 MG	34567 F	P8019	Updated		Q3	2023	525.00	\$0.00	\$0.00		12/31/2025
23 09/01/2025	J0003	INJECTION, LIONZOLOMIDE, 1 MG	34567 F	P8019	Initial		Q3	2024	871.00	\$0.00	\$0.00		12/31/2025
24 09/01/2025	J0003	INJECTION, LIONZOLOMIDE, 1 MG	34567 F	P8019	Updated		Q4	2023	0.00	\$0.00	\$0.00		12/31/2025
25 09/01/2025	J0003	INJECTION, LIONZOLOMIDE, 1 MG	34567 F		Initial		04	2024	1,335.00	\$3,171.39	\$3,171.39		12/31/2025
26		,,							_,	Total Amount Due	\$1,215,113.32		
27													


Payments




Payments Payable




Payments Pending



Payments Submitted




TPA Resources




CMS ASP Website


Discarded Drugs Page



ASP Education & Outreach Page



ASP Events Page



Program Overview

An overview of the Discarded Drug Program requires manufacturers of certain Part B Drugs to pay a refund to CMS for the portion of the drug that is discarded.

- Criteria
- Reporting
- Calculation
- Billing
- Payment
- Enforcement and Penalty



Discarded Drug Program Overview

Generally, when a separately payable drug from a single-dose container or single-use package is administered to an individual enrolled in Medicare Part B. Medicare pays the provider or facility for both administered and discarded amounts of the drug, up to the full labeled amount of the product. Section 90004 of the Infrastructure Investment and Jobs Act (IIJA) (Pub. L. 117–58. November 15, 2021) amended section 1847A of the Social Security Act (the Act) by adding provisions that require manufacturers to provide a refund to CMS for certain discarded amounts from a single-dose container or single-use package drug. Generally, the refund amount is the amount of payment for discarded amounts of a refundable drug (described below) that exceeds an applicable percentage, which is required to be at least 10 percent of total charges for the drug in a given calendar quarter. For specific calculations for new refund quarters, and updated refund quarters, refer to 42 CFR \$4.14.940(c).

Criteria

Manufacturers required to refund CMS for discarded amounts are those that manufacture refundable single dose container or single use package drugs (hereinafter referred to as refundable drugs), which are defined as singlesource drugs, biologicals, or biosimilar biological products for which payment has been made under Medicare Part B and that are furnished from a single dose container or single-use package, Exclusions from the definition of refundable drugs, as described in 42 CFR 8 141-902, and 87 FR 69719, include:

- · Radiopharmaceuticals (therapeutic or diagnostic) or imaging agents
- Certain drugs or biologicals requiring filtration during the preparation process (prior to dilution and administration) for which unused portions must be discarded after the filtration process
- Drugs approved or licensed by FDA on or after November 15, 2021, until the last day of the sixth full quarter
 for which the drug has been marketed (as reported to CMS) for the first reported sale for any NDCs of such
 drug

Reporting

CMS requires providers and suppliers to use the JW modifier on all claims for separately payable drugs with discarded drug amounts from single-use containers or single-use packages separately payable under Part B to identify and monitor billing and payment for discarded amounts of drugs. In submitting claims to Medicare, providers must indicate the number of billing units of the drug that were discarded using the JW modifier. Use of the JZ modifier is required on claims for drugs from single-dose containers or single-use packages separately payable under Part B when there are no discarded amounts. For more information on the JZ and JW modifiers, please review the JW. JZ Modifiers FAD (PDP) document.

Calculation

The refund amount is the amount by which the product of the number of discarded units and the payment limit exceeds the applicable percentage of the estimated total allowed charges for the drug for a given quarter, which is required to be at least 10 percent of total charges for the drug in a given calendar quarter (42 CTR \$ 414.940). Medicare Part B drug payment limits are published and effective on a quarterly basis. CMS uses the published payment limits to calculate the refund due for each new refund quarter to.

- Step (1): Multiplying the total number of discarded drug units based on the JW modifier submitted on all
 applicable claims for the quarter and the drug's payment limit, as determined under section 1847A(b)(1)(B) or
 (C) of the Act, for the quarter.
- Step (2): Multiplying the applicable percentage by the total allowed charges for the drug for the quarter, and
- . Step (3): Subtracting the product calculated in step (2) from the product calculated in step (1).

Please note: Applicable percentages may vary based on refundable drugs' unique circumstances and are described further in 42 CFR 5.414.940(d). Manufacturers may apply for an adjustment to their drug's applicable percentage. Application instructions are provided on the CMS Discarded Drugs website.

Billing

Manufacturer reports will be issued through the Manufacturer Payment Portal (MPP). CMS will issue an annual report to all manufacturers of refundable drugs, which will include the total number of units discarded based on the JW modifier and the refund amount calculated for each quarter. Manufacturers have an opportunity to submit an error report to CMS within 30 days after receipt of their report.

Payment

Manufacturers will be able to pay any refunds due through the MPP. Payment for refund amounts specified in the refund report is due by December 31 of the year in which the report is sent, except for the Initial Report for calendar quarters in 2023, which is due no later than February 28, 2025. If an error report is pending, payment will be due on the due date of the initial report or no later than 30 days after the error report has been resolved, whichever is later. (42 CTR 4.14 940)(YII.and (12)).

Enforcement and Penalty

Manufacturers of refundable drugs who do not comply with the requirement set forth at <u>42 CFR 5 414 940(b)</u> are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in <u>42 CFR 5 414 940(c)</u>.

For more information visit: <u>CMS Discarded Drugs Website</u> Contact us at: <u>DiscardedDrugs@cms.hhs.gov</u> Published: November 2024

Checklist

- Instructions on how to complete key program tasks
- Support information



Discarded Drug Program Manufacturer Quick Reference

Manufacturers play an active role in the discarded drug refund calculation process, from timely input of quarterly data to accurate record keeping. This quick reference guide of highlevel steps is designed to aid manufacturers during the discarded drug refund calculation process and to ensure compliance with legislation to avoid civil monetary penalties. For more information, visit the CMS Discarded Drugs website. Contact us at: DiscardedDrugs@cms.hhs.gov.



Request a P Number

CMS uses P Numbers to identify manufacturer accounts in the Health Plan Management System (HPMS) for various programs such as the Inflation Reduction Act's Medicare Prescription Drug Inflation Rebate Program and the Medicare Part B Discarded Drug Program. If you are new to the Discarded Drug Program, and have not been issued a P Number, please submit the following information via email to DiscardedDrugs@cms.hhs.gov to request a P Number:

- Manufacturer Legal Name
- Data Universal Numbering System (DUNS) Number
- Employer Identification Number (EIN)
- Primary Contact First and Last Name
- o Primary Contact Email Address
- Primary Contact Phone Number
- Subject Line of the Email Should Read "[Manufacturer Name] Request for P Number"

After you send your request, CMS will contact you should we require any additional information to issue a P Number. Once your P Number is issued, a representative from Palmetto GBA, a contractor serving as CMS' third-party administrator (TPA) for the invoicing and payment processes, will reach out to begin the HPMS onboarding process.

Error Reports

Manufacturers have 30 days after the issuance of their refund report(s) to assert that there have been one or more errors in the report. To submit a dispute for each asserted error, provide the following information in a written request to DiscardedDrugs@cms.hhs.gov.

- Manufacturer name and address
- Name, telephone, and email address of one or more employees of the manufacturer

For a Mathematical Calculation Error	For Any Other Asserted Error
 The specific calculation element(s) that the manufacturer disputes The proposed corrected calculation 	 An explanation of the nature of the error How the error affects the refund calculation An explanation of why the manufacturer believes that an error occurred The proposed correction to the error An explanation of why CMS should use the proposed corrected data

What's Next?

- ✓ Verify system access.
- ✓ Add or update Electronic Funds Transfer (EFT) information now.
- ✓ View reports on or after September 1, 2025.
- ✓ Pay refund amounts due by December 31, 2025.

Q&A



Closing Remarks

- Discarded Drugs webpage
- Technical Support (TPA)
 - tpaoperations@tpadministrator.com
 - 1-877-534-2772 (Option 1)
- Feedback and Other Questions
 - <u>DiscardedDrugs@cms.hhs.gov</u>

